Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Protalix Biotherapeutics (NYSEMKT:PLX) is the #1 top healthcare stock out of 1136 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Protalix Biotherapeutics (NYSEMKT:PLX) is: Value: B, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: B.

Protalix Biotherapeutics (NYSEMKT:PLX) has a Due Diligence Score of 26, which is equal to the healthcare sector average of 26. It passed 8 out of 33 due diligence checks and has average fundamentals. Protalix Biotherapeutics has seen its stock return 37.6% over the past year, overperforming other healthcare stocks by 93 percentage points.

Protalix Biotherapeutics has an average 1 year price target of $15.00, an upside of 772.09% from Protalix Biotherapeutics's current stock price of $1.72.

Protalix Biotherapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Protalix Biotherapeutics, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Ptc Therapeutics (NASDAQ:PTCT) is the #2 top healthcare stock out of 1136 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Ptc Therapeutics (NASDAQ:PTCT) is: Value: A, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Ptc Therapeutics (NASDAQ:PTCT) has a Due Diligence Score of 38, which is 12 points higher than the healthcare sector average of 26. It passed 12 out of 33 due diligence checks and has average fundamentals. Ptc Therapeutics has seen its stock return 42.45% over the past year, overperforming other healthcare stocks by 98 percentage points.

Ptc Therapeutics has an average 1 year price target of $61.85, an upside of 39.83% from Ptc Therapeutics's current stock price of $44.23.

Ptc Therapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Ptc Therapeutics, 46.15% have issued a Strong Buy rating, 15.38% have issued a Buy, 23.08% have issued a Hold, while 0% have issued a Sell rating, and 15.38% have issued a Strong Sell.

Phibro Animal Health (NASDAQ:PAHC) is the #3 top healthcare stock out of 1136 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Phibro Animal Health (NASDAQ:PAHC) is: Value: A, Growth: A, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: B.

Phibro Animal Health (NASDAQ:PAHC) has a Due Diligence Score of 42, which is 16 points higher than the healthcare sector average of 26. It passed 15 out of 38 due diligence checks and has strong fundamentals. Phibro Animal Health has seen its stock return 26.95% over the past year, overperforming other healthcare stocks by 83 percentage points.

Phibro Animal Health has an average 1 year price target of $21.50, a downside of -4.32% from Phibro Animal Health's current stock price of $22.47.

Phibro Animal Health stock has a consensus Sell recommendation according to Wall Street analysts. Of the 2 analysts covering Phibro Animal Health, 0% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 50% have issued a Strong Sell.

Out of 70 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Jade Biosciences (NASDAQ:JBIO) has an annual dividend yield of 27.75%, which is 25 percentage points higher than the healthcare sector average of 2.45%.

Jade Biosciences's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 13.16%, which is 11 percentage points higher than the healthcare sector average of 2.45%. Select Medical Holdings's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Select Medical Holdings's dividend has not shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 32.4% indicates that its high dividend yield is sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 10.6%, which is 8 percentage points higher than the healthcare sector average of 2.45%.

Siga Technologies's dividend payout ratio of 88.2% indicates that its high dividend yield is sustainable for the long-term.

Healthcare stocks were down -0.43% in the last day, and down -2.62% over the last week. Iovance Biotherapeutics was the among the top losers in the healthcare sector, dropping -44.79% yesterday.

Iovance Biotherapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results. Also, HC Wainwright lowered its price target on the spot from $32 to $20.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Biote (NASDAQ:BTMD) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biote has a valuation score of 29, which is 13 points higher than the healthcare sector average of 16. It passed 2 out of 7 valuation due diligence checks.

Biote's stock has dropped -36% in the past year. It has overperformed other stocks in the healthcare sector by 20 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 8.86% in the past year. It has overperformed other stocks in the healthcare sector by 65 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 14, which is -2 points higher than the healthcare sector average of 16. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates IRWD a Valuation Rating of "A".

Ironwood Pharmaceuticals's stock has dropped -89.48% in the past year. It has underperformed other stocks in the healthcare sector by -34 percentage points.

52.64% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 55.23% over the next year.

5.2% of healthcare stocks have a Zen Rating of A (Strong Buy), 10.88% of healthcare stocks are rated B (Buy), 45.22% are rated C (Hold), 26.72% are rated D (Sell), and 11.97% are rated F (Strong Sell).